Mapping adverse events and monitoring priorities for trastuzumab deruxtecan use in metastatic breast cancer
This study highlights respiratory and gastrointestinal toxicities as major risks associated with T-DXd in metastatic breast cancer. Careful monitoring, early intervention, and patient education are essential to balance benefits and risks, while future research should focus on molecular mechanisms to enable precision medicine.
Authors
- Yongcheng Su (ORCID: https://orcid.org/0000-0001-6322-7681)
- Jing She
- Liyi Zhang
- Zhiwei Wu (ORCID: https://orcid.org/0000-0002-0672-948X)
- Li Li (ORCID: https://orcid.org/0000-0003-4802-8689)
- Ruidan Zhao
- Songsong Wang (ORCID: https://orcid.org/0000-0002-1234-2484)
- Wuda Huoshen (ORCID: https://orcid.org/0009-0002-9513-7669)
- Qiaolu Yang
- Qingmo Yang
- Yun Zhang
- Yilong Lin
- Anqi Qiu
- Shengjie Lin
- Peifen Lai
Institutions
- Guangxi University (CN)
- Guangxi Medical University (CN)
- Xiamen University (CN)
- Southwest Medical University (CN)
- First Affiliated Hospital of Xiamen University (CN)
Publication Details
- Journal
- International Journal of Surgery
- Published
- 2026-01-21
- DOI
- https://doi.org/10.1097/js9.0000000000004702
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00